Sequent Scientific has announced the resignation of VP Ashish Kakabalia from his senior management position, effective December 23, 2025. The pharmaceutical company submitted the resignation intimation to BSE and NSE under Regulation 30 of SEBI Listing Regulations.

Executive Departure Details

Kakabalia served as Vice President - Business Development and Formulation and was designated as Senior Management Personnel. His resignation letter was dated December 23, 2025, making the departure effective immediately.

Regulatory Compliance

The company filed the resignation intimation with both stock exchanges as required under SEBI regulations. The disclosure was made pursuant to Regulation 30 of the SEBI Listing Regulations, with the requisite documentation submitted to BSE (Scrip Code: 512529) and NSE (Scrip Code: SEQUENT).

Company Communication

The resignation letter was addressed to CEO Rajaram Narayanan of Alivira Animal Health Ltd. In his resignation communication, Kakabalia mentioned that the decision was made as per mutual discussion and understanding, expressing gratitude and best wishes to the company and its employees.

The pharmaceutical company confirmed that the resignation was processed according to regulatory requirements, with Company Secretary and Compliance Officer Yoshita Vora handling the formal disclosure procedures.

Sequent Scientific has witnessed a major ownership restructuring as CA Hull Investments acquired a substantial 31.20% stake through the composite scheme of amalgamation that became effective on December 16, 2025. The acquisition marks a significant milestone in the company's transformation following the completion of its amalgamation with Viyash Life Sciences and other entities.

Major Stake Acquisition Details

CA Hull Investments received 13,61,60,231 equity shares of Sequent Scientific through the share exchange mechanism established under the amalgamation scheme. The acquisition was executed based on the approved share exchange ratio and has resulted in CA Hull Investments becoming part of the promoter group, while CA Harbor Investments, acting as persons in concert, holds 30.20% stake.

The acquisition was completed through allotment pursuant to the composite scheme of amalgamation involving multiple entities including Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Geninn Life Sciences Private Limited, and Sequent Research Limited.

Capital Structure Transformation

The amalgamation scheme has significantly altered Sequent Scientific's capital structure, with the total equity share capital expanding substantially to accommodate the new shareholding pattern. Following the merger, CA Harbor Investments' shareholding was diluted from 52.33% pre-merger to 30.20% post-merger.

Regulatory Compliance and SEBI Disclosure

CA Hull Investments, based in Mauritius and operating through designated directors, has fulfilled all regulatory disclosure requirements under SEBI Takeover Regulations. The company filed the mandatory disclosure under Regulation 10(6) on December 17, 2025, one day after the share allotment completion. The acquisition is exempt from open offer obligations under Regulation 10(1)(d)(ii) of SEBI Takeover Regulations as it was executed through a tribunal-approved amalgamation scheme.

The acquisition represents a strategic consolidation within the pharmaceutical sector, with CA Hull Investments now holding significant influence in Sequent Scientific's operations and strategic direction. The transaction was executed without any encumbrances, pledges, or non-disposal undertakings, providing clear ownership rights to the acquiring entity. CA Hull Investments is represented by director Purnima Boyjonauth Bhogun and operates through Apex Fund Corporate Services (Mauritius) Ltd.